PRELIMINARY COST-EFFECTIVENESS ANALYSIS OF PROTON BEAM THERAPY IN PATIENTS WITH HEPATOCELLULAR CARCINOMA IN JAPAN

被引：0
|
作者：
Moriwaki, K. [1 ]
Katoh, N. [2 ]
Hayashi, H. [2 ]
Miyakoshi, T. [2 ]
Terashima, K. [3 ]
Murayama, S. [4 ]
Suzuki, M. [5 ]
Okumura, T. [6 ]
Araya, M. [7 ]
Hojo, H. [8 ]
Iwata, H. [9 ]
机构：
[1] Ritsumeikan Univ, Kyoto 26, Japan
[2] Hokkaido Univ Hosp, Sapporo, Hokkaido, Japan
[3] Hyogo Ion Beam Med Ctr, Tatsuno, Hyogo, Japan
[4] Shizuoka Canc Ctr, Shizuoka, Japan
[5] Southern Tohoku Proton Therapy Ctr, Fukushima, Japan
[6] Univ Tsukuba, Ibaraki, Japan
[7] Aizawa Hosp, Nagano, Japan
[8] Natl Canc Ctr Hosp East, Chiba, Japan
[9] Nagoya City Univ, West Med Ctr, Nagoya, Aichi, Japan
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE361
引用
收藏
页码：S406 / S406
页数：1
相关论文
共 50 条
  • [21] Proton beam therapy for aged patients with hepatocellular carcinoma
    Hata, M.
    Tokuuye, K.
    Sugahara, S.
    Tohno, E.
    Nakayama, H.
    Fukumitsu, N.
    Abei, M.
    Shoda, J.
    Minami, M.
    Akine, Y.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 69 (03): : S305 - S305
  • [22] Cost-Effectiveness Analysis of Intrathecal Baclofen Therapy in Japan
    Hattori, Naoyuki
    Hirayama, Teruyasu
    Katayama, Yoichi
    NEUROLOGIA MEDICO-CHIRURGICA, 2012, 52 (07) : 482 - 487
  • [23] ASSESSING THE ROBUSTNESS OF A COST-EFFECTIVENESS ANALYSIS OF LENVATINIB VERSUS SORAFENIB IN UNRESECTABLE HEPATOCELLULAR CARCINOMA IN JAPAN
    Ikeda, S.
    Kudo, M.
    Izumi, N.
    Kaneko, S.
    Kobayashi, M.
    Azuma, M.
    Copher, R.
    Virabhak, S.
    Mitchell, D.
    Meier, G.
    Ishii, M.
    VALUE IN HEALTH, 2018, 21 : S46 - S46
  • [24] Cost-effectiveness analysis of cabozantinib as second-line therapy in advanced hepatocellular carcinoma
    Liao, Weiting
    Huang, Jiaxing
    Hutton, David
    Zhu, Guiqi
    Wu, Qiuji
    Wen, Feng
    Bai, Liangliang
    Li, Qiu
    LIVER INTERNATIONAL, 2019, 39 (12) : 2408 - 2416
  • [25] Cost-effectiveness analysis of durvalumab plus tremelimumab as first-line therapy in patients with unresectable hepatocellular carcinoma
    Liao, Weiting
    Xu, Huiqiong
    Hutton, David
    Wu, Qiuji
    Yang, Yang
    Feng, Mingyang
    Lei, Wanting
    Bai, Liangliang
    Li, Junying
    Li, Qiu
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [26] Cost-effectiveness of Pembrolizumab as a Second-Line Therapy for Hepatocellular Carcinoma
    Chiang, Chi-leung
    Chan, Sik-kwan
    Lee, Shing-fung
    Wong, Irene Oi-ling
    Choi, Horace Cheuk-wai
    JAMA NETWORK OPEN, 2021, 4 (01)
  • [27] Proton beam therapy for hepatocellular carcinoma
    Yeung, Rosanna H.
    Chapman, Tobias R.
    Bowen, Stephen R.
    Apisarnthanarax, Smith
    EXPERT REVIEW OF ANTICANCER THERAPY, 2017, 17 (10) : 911 - 924
  • [28] Posttransplant Hepatocellular Carcinoma Surveillance A Cost-effectiveness and Cost-utility Analysis
    Hessheimer, Amelia J.
    Vargas-Martinez, Ana Magdalena
    Trapero-Bertran, Marta
    Navasa, Miquel
    Fondevila, Constantino
    ANNALS OF SURGERY, 2023, 277 (02) : E359 - E365
  • [29] Cost-Effectiveness of Sorafenib Versus Selective Internal Radiation Therapy for Patients with Advanced Hepatocellular Carcinoma
    Parikh, Neehar Dilip
    Singal, Amit G.
    Kulik, Laura M.
    Hutton, David
    HEPATOLOGY, 2018, 68 : 532A - 533A
  • [30] Proton beam therapy for hepatocellular carcinoma patients with severe cirrhosis
    Hata, M.
    Tokuuye, K.
    Sugahara, S.
    Kagei, K.
    Fukumitsu, N.
    Hashimoto, T.
    Ohnishi, K.
    Ohara, K.
    Matsuzaki, Y.
    Akine, Y.
    EJC SUPPLEMENTS, 2005, 3 (02): : 224 - 225
12345